These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 10481813)

  • 1. Is the societal perspective in cost-effectiveness analysis useful for decision makers?
    Russell LB; Fryback DG; Sonnenberg FA
    Jt Comm J Qual Improv; 1999 Sep; 25(9):447-54. PubMed ID: 10481813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The once and future application of cost-effectiveness analysis.
    Berger ML
    Jt Comm J Qual Improv; 1999 Sep; 25(9):455-61. PubMed ID: 10481814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Good research practices for measuring drug costs in cost effectiveness analyses: issues and recommendations: the ISPOR Drug Cost Task Force report--Part I.
    Hay JW; Smeeding J; Carroll NV; Drummond M; Garrison LP; Mansley EC; Mullins CD; Mycka JM; Seal B; Shi L
    Value Health; 2010; 13(1):3-7. PubMed ID: 19874571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine.
    Russell LB; Gold MR; Siegel JE; Daniels N; Weinstein MC
    JAMA; 1996 Oct; 276(14):1172-7. PubMed ID: 8827972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices--budget impact analysis.
    Mauskopf JA; Sullivan SD; Annemans L; Caro J; Mullins CD; Nuijten M; Orlewska E; Watkins J; Trueman P
    Value Health; 2007; 10(5):336-47. PubMed ID: 17888098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Good research practices for measuring drug costs in cost-effectiveness analyses: a societal perspective: the ISPOR Drug Cost Task Force report--Part II.
    Garrison LP; Mansley EC; Abbott TA; Bresnahan BW; Hay JW; Smeeding J
    Value Health; 2010; 13(1):8-13. PubMed ID: 19883405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Understanding costs and cost-effectiveness in critical care: report from the second American Thoracic Society workshop on outcomes research.
    Am J Respir Crit Care Med; 2002 Feb; 165(4):540-50. PubMed ID: 11850349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Striving for a Societal Perspective: A Framework for Economic Evaluations When Costs and Effects Fall on Multiple Sectors and Decision Makers.
    Walker S; Griffin S; Asaria M; Tsuchiya A; Sculpher M
    Appl Health Econ Health Policy; 2019 Oct; 17(5):577-590. PubMed ID: 31098947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The patient experience of patient-centered communication with nurses in the hospital setting: a qualitative systematic review protocol.
    Newell S; Jordan Z
    JBI Database System Rev Implement Rep; 2015 Jan; 13(1):76-87. PubMed ID: 26447009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ethics of allocating intensive care unit resources.
    Lanken PN; Terry PB; Osborne ML
    New Horiz; 1997 Feb; 5(1):38-50. PubMed ID: 9017677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-Effectiveness and Clinical Practice Guidelines: Have We Reached a Tipping Point?-An Overview.
    Garrison LP
    Value Health; 2016; 19(5):512-5. PubMed ID: 27565265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of market-based 'reform' on cultural values in health care.
    Curtin LL
    Semin Nurse Manag; 1999 Dec; 7(4):198-202. PubMed ID: 11013589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inconsistencies in the "societal perspective" on costs of the Panel on Cost-Effectiveness in Health and Medicine.
    Meltzer D; Johannesson M
    Med Decis Making; 1999; 19(4):371-7. PubMed ID: 10520672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A dollar is a dollar is a dollar--or is it?
    Brouwer WB; van Exel NJ; Baltussen RM; Rutten FF
    Value Health; 2006; 9(5):341-7. PubMed ID: 16961552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ethical perspectives of reimbursement under economic pressures.
    Marsee VD
    Crit Care Nurs Clin North Am; 2000 Sep; 12(3):365-72. PubMed ID: 11855240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk management frameworks for human health and environmental risks.
    Jardine C; Hrudey S; Shortreed J; Craig L; Krewski D; Furgal C; McColl S
    J Toxicol Environ Health B Crit Rev; 2003; 6(6):569-720. PubMed ID: 14698953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Future of Patients in Healthcare Evaluation: The Patient-Informed Reference Case.
    Slejko JF; Mattingly TJ; Mullins CD; Perfetto EM; dosReis S
    Value Health; 2019 May; 22(5):545-548. PubMed ID: 31104732
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incremental cost-effectiveness ratios (ICERs): the silence of the lambda.
    Gafni A; Birch S
    Soc Sci Med; 2006 May; 62(9):2091-100. PubMed ID: 16325975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing the effectiveness of disease and injury prevention programs: costs and consequences.
    MMWR Recomm Rep; 1995 Aug; 44(RR-10):1-10. PubMed ID: 7565538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness analysis in relation to budgetary constraints and reallocative restrictions.
    Adang E; Voordijk L; Jan van der Wilt G; Ament A
    Health Policy; 2005 Oct; 74(2):146-56. PubMed ID: 16153475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.